Vertaling van "european-level patient groups " (Frans → Nederlands) :

Pour consulter les détails sur l’aide financière octroyée aux organisations de patients internationales et européennes, cliquez ici pour 2008, 2009, 2010, 2011 et pour 2012. For detailed information on support from Pfizer to international and European-level patient groups, please click here for 2008, 2009, 2010, 2011 and for 2012.
Voor gedetailleerde informatie over de financiële bijdragen verleend aan internationale en Europese patiëntenorganisaties, klik hier voor 2008, 2009, 2010, 2011 en 2012.

ouble entry two step deoxyribonucleic acid hepatitis e antigen estimated date of delivery nzyme immunoassay evidence level enzyme-linked immunosorbent assay early-onset disease early-onset group B streptococcus European Union fasting plasma glucose fluorescent treponemal antibody absorbed test glutamic acid decarboxylase group B streptococcus glucose challenge test Guideline Development Group gestational diabetes mellitus general practitioner good practice point glucose tolerance test haemoglobin hepatitis B immune globulin hepatitis B surface antigen hepatitis B virus human chorionic gonadotrophin (can be total or free
deoxyribonucleic acid hepatitis e antigen estimated date of delivery nzyme immunoassay evidence level enzyme-linked immunosorbent assay early-onset disease early-onset group B streptococcus European Union fasting plasma glucose fluorescent treponemal antibody absorbed test glutamic acid decarboxylase group B streptococcus glucose challenge test Guideline Development Group gestational diabetes mellitus general practitioner good practice point glucose tolerance test haemoglobin hepatitis B immune globulin hepatitis B surface antigen hepatitis B virus human chorionic gonadotrophin (can be total or free

European Commission, High level group on innovation and provision of medicines, recommendations for action. 7 May 2002, G10 medicines report. [http ...]
European Commission, High level group on innovation and provision of medicines, recommendations for action., 7 May 2002, G10 medicines report. [http ...]